Hutchison China MediTech (HCM)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 863.2 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 6.12 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | $m | |||||||||
| Operating Profit | $m | |||||||||
| Net Profit | $m | |||||||||
| EPS Reported | $ | |||||||||
| EPS Normalised | $ | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | $ | |||||||||
| Capex ps | $ | |||||||||
| Free Cashflow ps | $ | |||||||||
| Dividends | ||||||||||
| Dividend ps | $ | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | $m | |||||||||
| Working Capital | $m | |||||||||
| Net Fixed Assets | $m | |||||||||
| Net Debt | $m | |||||||||
| Book Value | $m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | $ | -5.1% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Hutchison China MediTech Limited revenues increased 18% to $195.4M. Net income before extraordinary items increased from $2.1M to $6.8M. Revenues reflect China Healthcare segment increase of 28% to $177.9M, Consumer Products Hong Kong segment increase of 14% to $8.6M, PRC segment increase of 19% to $186.1M, Hong Kong segment increase of 14% to $8.6M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 1 | 0 | 2 |
Hutchison China MediTech Limited (Chi-Med) is a holding company. The Company is principally engaged in the manufacturing, distribution and sales of Chinese medicine and health products. It operates in three segments: China healthcare, which consists of development, manufacture, distribution and sale of over the counter products, prescription products, and health supplements products; Drug R&D that includes drug discoveries and other pharmaceutical research and development activities, and the provision of research and development services, and Consumer products that include sales of healthcare oriented consumer products and services. During the year ended December 31, 2011, Hutchison MediPharma Limited, a subsidiary of Chi-Med acquired 50% interest of ChuanXinLian R&D Limited. During 2011, Hutchison Whampao Guangzhou Baiyunshan Chinese Medicine Company Limited, a jointly controlled entity of Chi-Med acquired 60% in Guanbao Pharmaceutical Company Limited.
Directors: Simon To (Chmn.) 60, Christian Hogg (CEO) 46, Chig Fung Cheng (CFO) 45, Edith Shih (Secy.) 61,
No. of Employees: 0 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 52,048,448 |
| Free Float | 14.7m (28.2%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share, FTSE Aim 100, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | 22nd Floor,Hutchison House 10 Harcourt Road, Hong Kong |
| Web | http://www.chi-med.com |
| Phone | +852 21281188 |
| Contact | Christian Hogg (Chief Executive Officer, Executive Director) |
| Registrar | Computershare Investor Service (Channel Islands) Ltd |
| Auditors | PricewaterhouseCoopers Hongkong |
| 10th May | Result of AGM |
| 24th Apr | Global Phase III UC trial initiated with HPML-004 |
| 12th Apr | Nutrition Science Partners JV Approved |
| 9th Apr | 2012 Annual Report and Notice of AGM |
| 8th Apr | Data Presentations at AACR |
| 26th Mar | Final Results |
Recent ↓
